1 Little, M., Kipriyanov, S. M., Le Gall, F., and Moldenhauer, G. (2000) Of mice and men: hybridoma and recombinant antibodies. Immunol. Today 21, 364-370.
2. Kohler, G. and Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497.
3 Kundu, P. K., Prasad, N. S., and Datta, D. (1998) Monoclonal antibody: high density culture of hybridoma cells and downstream processing for IgG recovery. Indian J. Exp. Biol. 36, 125-135.
4 VanAntwerp, J. J. and Wittrup, K. D. (2000) Fine affinity discrimination by yeast surface display and flow cytometry. Biotechnol. Prog. 16, 31-37.
5 Feldhaus, M. J., Siegel, R. W., Opresko, L. K., et al. (2003) Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat. Biotechnol. 21, 163-170.
6 Tokushige, K., Moradpour, D., Wakita, T., Geissler, M., Hayashi, N., and Wands, J. R. (1997) Comparison between cytomegalovirus promoter and elongation factor-1 alpha promoter-driven constructs in the establishment of cell lines expressing hepatitis C virus core protein. J. Virol. Methods 64, 73-80.
7 Bebbington, C. R., Renner, G., Thomson, S., King, D., Abrams, D., and Yarranton, G. T. (1992) High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology (N Y) 10, 169-175.
8 Bebbington, C. R. and Lambert, K. (1994) Genetic stability and product consistency of rDNA-derived biologicals from mammalian cells. Dev. Biol. Stand. 83, 183-184.
9 Birch, J. R. and Froud, S. J. (1994) Mammalian cell culture systems for recombinant protein production. Biologicals 22, 127-133.
10 Way, J. C., Lauder, S., Brunkhorst, B., et al. (2005) Improvement of Fc-erythro-poietin structure and pharmacokinetics by modification at a disulfide bond. Protein Eng. Des. Sel. 18, 111-118.
11 Leenaars, M. and Hendriksen, C. F. (2005) Critical steps in the production of polyclonal and monoclonal antibodies: evaluation and recommendations. Ilar. J. 46, 269-279.
12 Dinnis, D. M. and James, D. C. (2005) Engineering mammalian cell factories for improved recombinant monoclonal antibody production: lessons from nature? Biotechnol. Bioeng. 91, 180-189.
13 Mathew, S. O., Kumaresan, P. R., Lee, J. K., Huynh, V. T., and Mathew, P. A. (2005) Mutational analysis of the human 2B4 (CD244)/CD48 interaction: Lys68 and Glu70 in the V domain of 2B4 are critical for CD48 binding and functional activation of NK cells. J. Immunol. 175, 1005-1013.
14 Winter, G., Griffiths, A. D., Hawkins, R. E., and Hoogenboom, H. R. (1994) Making antibodies by phage display technology. Annu. Rev. Immunol. 12, 433-455.
15 Hoogenboom, H. R., Henderikx, P., and de Haard, H. (1998) Creating and engineering human antibodies for immunotherapy. Adv. Drug Deliv. Rev. 31, 5-31.
16 Feldhaus, J. M., Siegel, R. W., Feldhaus, J. M. and Wittrup, K. D. (2003) Yeast Display scFv Antibody Library User's Manual Pacific Northwest National Laboratory. pp. 1-44.
17 Hu, P., Mizokami, M., Ruoff, G., Khawli, L. A., and Epstein, A. L. (2003) Generation of low-toxicity interleukin-2 fusion proteins devoid of vasoperme-ability activity. Blood 101, 4853-4861.
18 Ma, Q., DeMarte, L., Wang, Y., Stanners, C. P., and Junghans, R. P. (2004) Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins. Cancer Gene. Ther. 11, 297-306.
19 Ruocco, A., Nicole, O., Docagne, F., et al. (1999) A transforming growth factor-beta antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury. J. Cereb. Blood Flow Metab. 19, 1345-1353.
Was this article helpful?